Identification and Management after Failure of Local Prostate Cancer Treatments (2026)
The Evolving Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-Based Discussion (2026): Identification and Management after Failure of Local Prostate Cancer Treatments Speaker: Stephen A. Boorjian, MD CME Available: https://cme.auanet.org/URL/AUASUO261ONL ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Astellas, AstraZeneca, Blue Earth Diagnostics, Inc., Lantheus Medical Imaging, Merck & Co. Inc., Novartis Pharmaceuticals Corporation and Pfizer, Inc.
▶︎
Advanced Prostate Cancer in the News 2026: A Case-Based Multidisciplinary Update (2026)
▶︎
Gleason 4 & Cribriform #ProstateCancer | PROTECT Trial Data | #MarkScholzMD #AlexScholz #PCRI
▶︎
M1 CRPC: First and Second Line Treatment Options (2026)
▶︎
AUA Guidelines: Clinically Localized Prostate Cancer
▶︎
Next Generation Imaging (PSMA) and Introduction to Theranostics (2026)
▶︎
Gleason 3+4 vs 4+3: Which One Is More Dangerous?
▶︎
Intermediate risk prostate cancer
▶︎
OTEOB From ASCO 2026: What’s Changing in Prostate, Lung and Multiple Myeloma Research
▶︎
Surgery or Radiotherapy for Prostate Cancer? Here's What the Evidence Shows
▶︎
mHSPC: Chemo-hormonal Therapy and Treatment Intensification (2026)
▶︎
Genetic Testing in Advanced Prostate Cancer (2026)
▶︎
Multidisciplinary Care Model – Rationale and Approach for Building Your Team (2026)
▶︎
Beam Radiation Vs. Brachytherapy for #ProstateCancer | #MarkScholzMD #AlexScholz #PCRI
▶︎
Manipulating the Androgen Axis: Androgen Receptor Pathway Inhibitors in HSPC and CRPC (2026)
▶︎
Evolving Strategies in the Diagnosis and Treatment of Muscle-Invasive Bladder Cancer
▶︎
Relapsed Prostate Cancer | 2026 Mid-Year Update | Eugene Kwon, MD + Mark Moyad, MD Q&A #PCRI
▶︎
mCRPC Lu-177 PSMA and Beyond with Dr. William K. Oh
▶︎
Prostate Cancer Cure Explained: PSA, Recurrence, and Survival
▶︎
M1 CRPC: PARP Inhibitors and Precision Medicine (2026)
▶︎